Definium Therapeutics (DFTX)
NASDAQ:DFTX
Want to see DFTX full AI Analyst Report?
Earnings Data
Report Date
Aug 13, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.55Last Year’s EPS
-0.5Same Quarter Last Year
Strong Buy
Based on 13 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasizes strong clinical momentum (multiple Phase III programs with imminent topline readouts, Breakthrough Therapy designation in GAD, high statistical power in key studies), a clear commercialization plan and a solid cash position ($373.4M runway into 2028). These positives are tempered by materially higher operating expenses and a sizable YOY increase in net loss (driven by program investment and a non-cash warrant valuation change), design-related placebo risk from Phase II, and remaining regulatory and payer uncertainties that could affect timing and labeling. On balance, management’s message is forward-looking and execution-focused with meaningful near-term inflection points.Company Guidance
Late-Stage Clinical Progress — Multiple Phase III Readouts Imminent
DT120 ODT advancing with four ongoing Phase III studies across MDD, GAD (Breakthrough Therapy designation), and PTSD expansion planned (HAVEN in 2027). Enrollment complete or nearly complete: EMERGE (MDD) = 149 participants (enrollment complete), VOYAGE (GAD) = 214 (complete), PANORAMA (GAD) = exceeded updated target of 200 and expected to complete enrollment this month. Topline timing: EMERGE later this quarter; VOYAGE early Q3; PANORAMA late Q3.
Robust Statistical Power and Study Design
VOYAGE and PANORAMA powered at 99%+ to detect a 5-point placebo-adjusted difference (based on blinded sample size re-estimations). EMERGE powered at 80% to detect a 5-point difference with statistical significance possible at just over a 3-point difference given nuisance parameter assumptions. Primary endpoints staggered (EMERGE: 6 weeks; VOYAGE & PANORAMA: 12 weeks) and Part B follow-up extends to one year with up to four additional open-label treatments to evaluate durability and retreatment patterns.
Strong Liquidity and Runway
Cash, cash equivalents and investments of $373.4 million at quarter-end, which management believes provides runway to fund planned operations through multiple anticipated clinical readouts and into 2028.
Commercial Opportunity and Launch Preparedness
Large addressable market identified (approx. 4.2 million U.S. adults who cycled through ≥2 treatments). Management estimates capturing 1% of TAM (deduplicated for MDD/GAD overlap) using Spravato pricing as a surrogate equates to roughly a $2 billion annual revenue opportunity. Company has a targeted launch plan (high-volume psychiatrists, centralized hub support, payer engagement) and is planning for J-code submission assumptions post-approval.
Investment in Capabilities to Support Potential Commercialization
Deliberate increase in investments to support Phase III execution, NDA preparation, market access, and commercialization readiness. Management describes increased R&D and G&A spending as intentional to prepare for pivotal data and potential launch.
Progress in Non-DT120 Programs (DT402)
Advancing a Phase II DT402 program in autism spectrum disorder (R-enantiomer of MDMA) with promising prosocial signals and a signal-of-efficacy study using patient-, caregiver-, clinician-reported measures and digital behavioral markers.
Operational Improvements — Shorter Patient Journey
Phase III uses an orally dissolving tablet formulation and revised end-of-session criteria to shorten the expected in-clinic patient monitoring window from 10–12 hours in Phase II toward a 5–8 hour target in Phase III, potentially improving clinic throughput and patient experience.
DFTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DFTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $23.20 | $22.05 | -4.96% |
Feb 26, 2026 | $17.29 | $17.45 | +0.93% |
Nov 06, 2025 | $11.34 | $11.70 | +3.17% |
Aug 05, 2025 | $9.64 | $9.89 | +2.59% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Definium Therapeutics (DFTX) report earnings?
Definium Therapeutics (DFTX) is schdueled to report earning on Aug 13, 2026, Before Open (Confirmed).
What is Definium Therapeutics (DFTX) earnings time?
Definium Therapeutics (DFTX) earnings time is at Aug 13, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DFTX EPS forecast?
DFTX EPS forecast for the fiscal quarter 2026 (Q2) is -0.55.